相关实验视频
Updated: Jul 15, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
探索基于植物的α-葡萄糖酶抑制剂:对抗2型糖尿病的有希望的竞争者
Sonali Kumari1, Ravi Saini1, Aditi Bhatnagar1
1School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, India.
Archives of physiology and biochemistry
|September 28, 2023
概括
自然化合物在抑制α-葡萄糖酶 (α-G) 方面表现有前途,通过调节血糖水平,为管理2型糖尿病 (T2D) 提供了潜在的替代方案.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 阿尔法-葡萄糖酶 (α-G) 酶促进小肠中的葡萄糖吸收,影响食后血糖水平.
- 餐后葡萄糖升高是导致2型糖尿病 (T2D),肥胖和心血管疾病的关键因素.
- 目前的α-G抑制剂具有不良影响,推动了对天然替代品的研究.
研究的目的:
- 系统地审查来自自然来源的生物活性化合物的α-G抑制潜力.
- 确定可以调节高血糖并可能管理T2D的天然化合物.
主要方法:
- 在主要的科学数据库 (Science Direct,Google Scholar,SciFinder,Web of Science,PubMed) 进行了全面的文献搜索,直到2023年5月.
- 系统审查方法,对α-G抑制化合物的数据进行整理和分析.
主要成果:
- 许多天然生物活性化合物,包括狼,乌尔索酸,奥莱阿诺酸和普胺,表现出显著的α-G抑制活性.
- 这些化合物显示出控制食后高血糖的潜力.
- 已识别的化合物为T2D管理提供了一个自然的方法.
结论:
- 来自自然来源的生物活性化合物具有相当大的α-G抑制潜力.
- 这些天然化合物代表了管理高血糖和2型糖尿病的有希望的治疗候选者.
- 对这些天然化合物的进一步研究可能会导致新的T2D治疗方法.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204
Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Oral Hypoglycemic Agents: Glinides
176
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K

